Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a Safety and Feasibility Study Evaluating Psilocybin (TRP-8802) Administration in Concert With Psychotherapy in the Treatment of Binge Eating Disorder

NCT05035927 is registered in ClinicalTrials.gov with TRYP Therapeutics as lead sponsor.

NCT NCT05035927
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05035927 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a Safety and Feasibility Study Evaluating Psilocybin (TRP-8802) Administration in Concert With Psychotherapy in the Treatment of Binge Eating Disorder
Lead sponsor
TRYP Therapeutics
Phase
Phase 2
Overall status
Completed
Start date
March 16, 2022
Completion date
June 7, 2024
Enrollment
5 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

binge eating disorder